drugset / Trial / NCT07572071
Safety and Feasibility of Bilateral Striatal Transplantation of DopaCell in Parkinson's Disease
Phase 1
Recruiting
6 enrolled
Royan Institute
Iran University of Medical Sciences · collabRoyan AtiTech Pharmed · collabShiraz University of Medical Sciences · collab
NaSingle-groupOpen-labelTreatment
Summary
Dopason is a phase I, open-label, multicenter, single-arm clinical trial designed to evaluate the safety and feasibility of intraputaminal transplantation of human embryonic stem cell-derived dopaminergic progenitor cells (DopaCells) in patients with moderately severe Parkinson's disease.
Timeline
- Start
- 2025-08-01
- Primary completion
- 2028-08-01
- Completion
- 2030-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DopaCell | Cell therapy | 1e+07 cells | Other |
| Background | Basiliximab | Monoclonal antibody | — | — |
| Background | Prednisolone | Other / unclassified | — | — |
| Background | Tacrolimus | Small molecule | — | — |